Feb 26, 2024 8:30 am EST LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
Jan 29, 2024 8:30 am EST First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
Nov 13, 2023 8:30 am EST LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
Oct 16, 2023 8:30 am EDT LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration
Oct 9, 2023 8:30 am EDT LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach
Sep 20, 2023 8:30 am EDT LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer
Jul 20, 2023 4:05 pm EDT LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
Jul 18, 2023 8:00 am EDT LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
Jul 17, 2023 8:30 am EDT Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
